Related references
Note: Only part of the references are listed.Detailed Mechanistic Analysis of Gevokizumab, an Allosteric Anti-IL-1β Antibody with Differential Receptor-Modulating Properties
Hassan Issafras et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Behcet's Syndrome
Gulen Hatemi et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2013)
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study
Ahmet Gul et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Claudia Cavelti-Weder et al.
DIABETES CARE (2012)
The Emerging Role of Interleukin-1β in Autoinflammatory Diseases
Helen J. Lachmann et al.
ARTHRITIS AND RHEUMATISM (2011)
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1 beta-mediated diseases
Alexander M. Owyang et al.
MABS (2011)
Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity
Marina K. Roell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
EULAR recommendations for the management of Behcet disease
G. Hatemi et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis)
Ilknur Tugal-Tutkun et al.
INTERNATIONAL OPHTHALMOLOGY (2008)
Standard and novel therapeutic approaches to Behcet's disease
Ahmet Gul
DRUGS (2007)
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop
DA Jabs et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2005)
Uveitis in Behcet disease: An analysis of 880 patients.
I Tugal-Tutkun et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)
Effect of infliximab on sight-threatening panuveitis in Behcet's disease
PP Sfikakis et al.
LANCET (2001)
Share Paper
